Join
Live feed
·
PRReleasevia Quantisnow
Interpace Biosciences, Inc. logo

Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk

ByQuantisnow·Wall Street's wire, on your screen.
IDXG· Interpace Biosciences, Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IDXG (Interpace Biosciences, Inc.) and more on Quantisnow.